Indication
Dense Deposit Disease
8 clinical trials
6 products
Product
PegcetacoplanClinical trial
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With PegcetacoplanStatus:
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGNStatus: Active (not recruiting), Estimated PCD: 2023-02-27
Clinical trial
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2027-07-01
Clinical trial
A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G), With an Open-label ExtensionStatus: Completed, Estimated PCD: 2019-12-11
Product
PlaceboProduct
APL-2Product
DanicopanClinical trial
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)Status: Active (not recruiting), Estimated PCD: 2020-04-16
Clinical trial
An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471Status: Terminated, Estimated PCD: 2021-03-29
Clinical trial
Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 GlomerulopathyStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AliskirenProduct
Enalapril